Hopveus® (Sodium Oxybate)
Alcohol Use Disorder (AUD) - maintenance of abstinence
Phase 3/ApprovalActive
Key Facts
Indication
Alcohol Use Disorder (AUD) - maintenance of abstinence
Phase
Phase 3/Approval
Status
Active
Company
About D&A Pharma
D&A Pharma is a private, European biopharmaceutical company specializing in repurposing and reformulating known drugs for addiction treatment, particularly Alcohol Use Disorders (AUD). Its lead asset, Hopveus®, is a patented solid formulation of sodium oxybate (SMO) designed as an abuse-deterrent outpatient treatment for AUD, which recently had a key EU marketing authorization rejection overturned by the Court of Justice. The company operates with an integrated model covering R&D through commercialization across Europe, targeting niche therapeutic areas often overlooked by larger pharmaceutical firms.
View full company profile